COMMUNIQUÉS West-GlobeNewswire
-
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
21/05/2026 -
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
21/05/2026 -
NANOBIOTIX annonce les modalites definitives de son offre globale sursouscrite a hauteur de 85 millions d’euros
21/05/2026 -
GENFIT : Information financière du premier trimestre 2026 et point sur les activités de la Société
21/05/2026 -
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
21/05/2026 -
‘Pour La Passe’: Haleon Canada lance une campagne nationale avec Canada Soccer pour célébrer les petits gestes de santé derrière le bien-être des Canadiens
21/05/2026 -
NSK Dental Achieves Back-to-Back Top Ratings in Dental Product Shopper Peer Evaluations
21/05/2026 -
KOMO Biosciences Appoints Biologics Manufacturing Leader Darryl Sampey, PhD, to its Scientific Advisory Board
21/05/2026 -
Intuitive Announces Innovations to Advance Quintuple Aim
21/05/2026 -
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
21/05/2026 -
Tvardi Therapeutics to Participate in Upcoming Investor Events
21/05/2026 -
Genvor Appoints Donald Kalkofen as Chief Financial Officer
21/05/2026 -
‘For The Assist’: Haleon Canada launches national campaign with Canada Soccer to celebrate the small health supports behind Canadian wellbeing
21/05/2026 -
HNL Lab Medicine Receives 2026 Boomi Innovation Award for Advancing Integration and Automation in Healthcare
21/05/2026 -
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
21/05/2026 -
Medicana Strengthens Its International Sports Presence Through Expanded Healthcare Partnership with Fenerbahçe
21/05/2026 -
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
21/05/2026 -
Nanobiotix annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
21/05/2026 -
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
21/05/2026
Pages